VIAL
Home/Compounds/Noopept
RecoveryGrey AreaPreclinical

Noopept

About

About Noopept

Noopept is a synthetic dipeptide nootropic derived from piracetam with substantially greater potency and oral bioavailability. It is approved in Russia as a prescription nootropic for cognitive impairment and is used globally as a cognitive enhancer. Studies show improvements in memory, learning, and neuroplasticity markers. It is available as a research compound in the US.

Science

Mechanism of Action

Metabolized to cycloprolylglycine (a natural neuropeptide), it modulates AMPA receptors to enhance LTP and synaptic plasticity; also increases expression of BDNF and NGF in the hippocampus.

Dosing

Typical Protocol

10–30 mg oral or sublingual 1–2x daily; sublingual administration improves onset and bioavailability.

⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.

Regulatory

Legal Status in 2026

Grey Area

This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.

Evidence

Evidence Tier

Preclinical

Evidence primarily from animal studies, cell cultures, or small pilot human trials. Results are promising but have not yet been confirmed in large-scale human RCTs. Effects in humans may differ from animal models.

Find a Verified Provider

See which Vial-verified providers offer Noopept — with trust scores, legal credentials, and pricing transparency.

Browse all verified providers →